25,274 Shares in Moderna, Inc. (NASDAQ:MRNA) Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 25,274 shares of the company’s stock, valued at approximately $2,693,000.

Several other large investors have also recently added to or reduced their stakes in MRNA. V Square Quantitative Management LLC bought a new position in Moderna during the third quarter worth $189,000. LPL Financial LLC lifted its stake in Moderna by 7.2% during the third quarter. LPL Financial LLC now owns 115,782 shares of the company’s stock worth $11,959,000 after purchasing an additional 7,811 shares during the last quarter. Mariner LLC lifted its stake in Moderna by 5.2% during the third quarter. Mariner LLC now owns 20,242 shares of the company’s stock worth $2,091,000 after purchasing an additional 996 shares during the last quarter. Stifel Financial Corp lifted its stake in Moderna by 19.0% during the third quarter. Stifel Financial Corp now owns 75,871 shares of the company’s stock worth $7,837,000 after purchasing an additional 12,099 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in Moderna by 1.9% during the third quarter. Northern Trust Corp now owns 2,971,056 shares of the company’s stock worth $306,880,000 after purchasing an additional 55,177 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on MRNA. Oppenheimer raised their target price on Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a research note on Wednesday, June 12th. William Blair reiterated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Monday, June 3rd. Royal Bank of Canada raised their target price on Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a research note on Monday, June 3rd. Finally, Canaccord Genuity Group raised their target price on Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research note on Friday, May 3rd. Two analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $129.02.

Insider Buying and Selling

In related news, insider Shannon Thyme Klinger sold 1,296 shares of Moderna stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total transaction of $210,561.12. Following the transaction, the insider now directly owns 10,623 shares of the company’s stock, valued at $1,725,918.81. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $138.16, for a total value of $2,072,400.00. Following the transaction, the president now owns 1,457,089 shares of the company’s stock, valued at approximately $201,311,416.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Shannon Thyme Klinger sold 1,296 shares of Moderna stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total value of $210,561.12. Following the completion of the transaction, the insider now directly owns 10,623 shares in the company, valued at approximately $1,725,918.81. The disclosure for this sale can be found here. Insiders have sold a total of 411,255 shares of company stock valued at $55,846,531 over the last three months. Company insiders own 15.70% of the company’s stock.

Moderna Price Performance

NASDAQ:MRNA opened at $133.40 on Friday. The business’s 50-day moving average price is $131.68 and its 200 day moving average price is $110.08. The firm has a market cap of $51.12 billion, a P/E ratio of -8.51 and a beta of 1.54. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. The firm had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. Moderna’s revenue was down 91.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.19 earnings per share. As a group, sell-side analysts predict that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.